Switzerland-based Novartis has agreed to acquire dry eye drug Xiidra (lifitegrast ophthalmic solution) 5% from Japan-based Takeda, it was reported yesterday.
The deal is valued at USD3.4bn. According to the terms of the contract, Takeda is also eligible to secure up to an additional USD1.9bn in potential milestone payments from Novartis along with USD3.4bn upfront payment in cash. The deal is likely to be completed in the second half of 2019, subject to customary closing conditions including regulatory approvals. Under the deal, round 400 employees associated with Xiidra product and based in the US and Canada will join Novartis.
The product is said to be the first and only prescription treatment secured approval for the treatment of both signs and symptoms of dry eye by inhibiting inflammation caused by the disease. It received approval to treat signs and symptoms of dry eye disease in various markets including the US, Canada and Australia, and is also under regulatory assessment in a number of additional markets.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007